In vivo Efficacy and Pharmacokinetics of Optimized Apidaecin Analogs by Rico Schmidt et al.
ORIGINAL RESEARCH
published: 20 March 2017
doi: 10.3389/fchem.2017.00015
Frontiers in Chemistry | www.frontiersin.org 1 March 2017 | Volume 5 | Article 15
Edited by:
Maria Luisa Mangoni,
Sapienza University of Rome, Italy
Reviewed by:
Marco Scocchi,
University of Trieste, Italy
Lorenzo Stella,
University of Rome Tor Vergata, Italy
*Correspondence:
Ralf Hoffmann
bioanaly@rz.uni-leipzig.de
†
These authors have contributed
equally to this work.
Specialty section:
This article was submitted to
Chemical Biology,
a section of the journal
Frontiers in Chemistry
Received: 14 November 2016
Accepted: 28 February 2017
Published: 20 March 2017
Citation:
Schmidt R, Knappe D, Wende E,
Ostorházi E and Hoffmann R (2017) In
vivo Efficacy and Pharmacokinetics of
Optimized Apidaecin Analogs.
Front. Chem. 5:15.
doi: 10.3389/fchem.2017.00015
In vivo Efficacy and
Pharmacokinetics of Optimized
Apidaecin Analogs
Rico Schmidt 1, 2 †, Daniel Knappe 1, 2 †, Elisabeth Wende 1, 2, Eszter Ostorházi 3 and
Ralf Hoffmann 1, 2*
1 Faculty of Chemistry and Mineralogy, Institute of Bioanalytical Chemistry, Universität Leipzig, Leipzig, Germany, 2Center for
Biotechnology and Biomedicine, Universität Leipzig, Leipzig, Germany, 3 Institute of Medical Microbiology, Semmelweis
University, Budapest, Hungary
Proline-rich antimicrobial peptides (PrAMPs) represent promising alternative therapeutic
options for the treatment of multidrug-resistant bacterial infections. PrAMPs are
predominantly active against Gram-negative bacteria by inhibiting protein expression
via at least two different modes of action, i.e., blocking the ribosomal exit tunnel of
70S ribosomes (oncocin-type binding) or inhibiting the assembly of the 50S ribosomal
subunit (apidaecin-type binding). The in vivo efficacy and favorable biodistribution of
oncocins confirmed the therapeutic potential of short PrAMPs for the first time, whereas
the in vivo evaluation of apidaecins is still limited despite the promising efficacy of
apidaecin-analog Api88 in an intraperitoneal murine infection model. Here, the in vivo
efficacy of apidaecin-analog Api137 was studied, which rescued all NMRI mice from a
lethal intraperitoneal infection with E. coli ATCC 25922 when administered three times
intraperitoneal at doses of 0.6 mg/kg starting 1 h after infection. When Api88 and Api137
were administered intravenous or intraperitoneal at doses of 5 and 20 mg/kg, their
plasma levels were similarly low (<3 µg/mL) and four-fold lower than for oncocin-analog
Onc72. This contradicted earlier expectation based on the very low serum stability of
Api88 with a half-life time of only ∼5 min compared to ∼6 and ∼3 h for Api137 and
Onc72, respectively. Pharmacokinetic data relying on a sensitive mass spectrometry
method utilizing multiple reaction monitoring and isotope-labeled peptides revealed that
Api88 and Api137 were present in blood, urine, and kidney, and liver homogenates at
similar levels accompanied by the same major metabolites comprising residues 1–16
and 1–17. The pretended discrepancy was solved, when all peptides were incubated
in peritoneal lavage. Api137 was rapidly degraded at the C-terminus, while Api88 was
rather stable despite releasing the same degradation products. Onc72 was very stable
explaining its higher plasma levels compared to Api88 and Api137 after intraperitoneal
administration illuminating its good in vivo efficacy. The data indicate that the degradation
of therapeutic peptides should be studied in serum and further body fluids. Moreover, the
high efficacy in murine infection models and the fast clearance of Api88 and Api137 within
∼60 min after intravenous and ∼90 min after intraperitoneal injections indicate that their
in vivo efficacy relates to the maximal peptide concentration achieved in blood.
Keywords: Api88, Api137, E. coli ATCC 25922, intraperitoneal infection, intraperitoneal lavage, mass spectrometry,
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INTRODUCTION
Antimicrobial peptides (AMPs) are considered as promising
alternatives to common antibiotics that threateningly lose their
therapeutic potentials against multidrug-resistant pathogens
(Fox, 2013; Wang et al., 2015). In contrast to approved
therapeutic peptide hormones, antimicrobial peptides have to
be administered at much higher doses, which may amplify
general drawbacks of peptide therapeutics. For example, the
diabetes peptide drugs exenatide and pramlintide are given
at daily doses of 20 µg (Byetta R©; ∼0.5 µg/kg) and 120 µg
(Symlin R©; ∼1.5 µg/kg; Heine et al., 2005; Hay et al., 2015),
while antimicrobial peptides are usually administered at 50- to
100-fold higher doses (>5 mg/kg) in order to achieve high
in vivo efficacies (Benincasa et al., 2010; Szabo et al., 2010;
Brunetti et al., 2016). This is also true for proline-rich AMPs
(PrAMPs), such as insect-derived oncocin and apidaecin analogs
that showed protective effects in murine intraperitoneal and
intramuscular infections with Escherichia coli ATCC 25922
and antibiotic-susceptible and -resistant Klebsiella pneumoniae
strains (Czihal et al., 2012; Knappe et al., 2012, 2015; Ostorhazi
et al., 2014; Schmidt et al., 2016). Mechanistically, cationic
AMPs first electrostatically interact with the negatively charged
surface of bacteria and—depending on the secondary structure—
act on the membrane or reach the periplasmic space possibly
by spontaneous translocation (Hancock, 1997; Brogden, 2005;
Scocchi et al., 2016). PrAMPs exhibit a therapeutically favorable
intracellular mode of action after translocating into the bacterial
cytoplasm by utilizing different transporter proteins/complexes,
such as SbmA, YjiL/MdtM, and YgdD (Mattiuzzo et al.,
2007; Runti et al., 2013; Krizsan et al., 2015a; Paulsen et al.,
2016). Internalized PrAMPs bind to chaperone DnaK and
70S ribosomes. While DnaK is most likely a binding partner
with possible transport functions (Otvos et al., 2000; Knappe
et al., 2011b, 2016a; Czihal et al., 2012; Zahn et al., 2013),
the 70S ribosome appears to be the major bacterial target. For
example, oncocin analogs Onc72 and Onc112 bind with Kd
values of 450 and 90 nmol/L, respectively, in a fluorescence
polarization assay to the exit tunnel, as recently revealed by X-
ray crystallography (Krizsan et al., 2014; Roy et al., 2015; Seefeldt
et al., 2015). Apidaecin-derived analogs Api88 and Api137
possess the same sequence, i.e., gu-ONNRPVYIPRPRPPHPRL
(O: ornithine, gu: N,N,N′,N′-tetramethylguanidino), and differ
only by the C-terminal amide and acid groups, respectively. They
bind to 70S ribosomes with considerably lower affinities (Kd =
1.2 and 0.56 µmol/L, respectively). Surprisingly, only oncocins
significantly inhibit cell free protein expression with IC50 values
of ∼0.2 µmol/L, whereas both apidaecins and oncocins inhibit
protein translation in E. coli equally efficient with IC50 values of
∼2 µmol/L. This different in vitro behavior appears to be related
to different inhibitionmechanisms. Api137 disturbs the assembly
of the 50S ribosomal subunit in E. coli leading to a protein
complex size of around 42S (Krizsan et al., 2015b). This unique
mode of action leads to high antimicrobial activities against E.
coli ATCC 25922 (MIC = 4 µg/mL) and other Gram-negative
bacteria. Both Api88 and Api137 possess in vitro very similar
antibacterial activities, but Api88 is much faster degraded in
mouse serum in vitro with a low half-life time of only 5 min
compared to 6 h for Api137 (Berthold et al., 2013). Api88 is
degraded C-terminally to virtually inactive Api1-17 and Api1-16.
Despite its low serum stability in vitro, Api88 was highly efficient
in a lethal NMRImousemodel of intraperitoneal sepsis providing
100% survival rates at doses of 1.25 mg/kg (Czihal et al., 2012).
In the present study, we investigated the efficacy of Api137
in the same NMRI mouse infection model, which indeed
turned out to be even better than for Api88. Focusing on
the pharmacokinetics, Api88 and Api137 were quantified by
reversed-phase (RP-) HPLC coupled online to an electrospray
ionization (ESI) mass spectrometer (MS) utilizing multiple
reaction monitoring (MRM) relative to isotope-labeled peptide
standards. Both peptides and their two major metabolites were
studied in blood, urine, and homogenates of kidney, liver, and
brain. Together with previous reports on the pharmacokinetics
and in vivo efficacy of Onc72 and Onc112 (Knappe et al., 2012;
Holfeld et al., 2015; Schmidt et al., 2016) the results presented
here for Api88 and Api137 provide the first comprehensive
representation of the therapeutic potential of insect-derived
PrAMPs.
MATERIALS AND METHODS
Peptides
Apidaecin derivatives (Table S1) were synthesized on solid phase
using the 9-fluorenylmethoxycarbonyl/tert-butyl (Fmoc/tBu)-
strategy and in situ activation withN,N′-diisopropylcarbodiimide
in the presence of N-hydroxybenzotriazole as described
previously (Czihal et al., 2012; Berthold et al., 2013). Isotope-
labeled Fmoc-Pro-OH [97–99% 13C5, 97–99% 15N] (Euriso-Top
GmbH, Saarbrücken, Germany) was coupled manually overnight
using a 1.5-fold excess of the amino acid derivative. Peptides were
cleaved with TFA containing a scavenger mixture (12.5% v/v;
ethandithiole, m-cresol, water, and thioanisole, 1/2/2/2 v/v/v/v)
and afterwards precipitated and washed three times with cold
diethyl ether. Peptides were purified by RP-HPLC on a Jupiter
C18-column (ID: 10 mm) using a linear aqueous acetonitrile
gradient containing TFA (0.1% v/v) as ion pair reagent. Purities
were judged by RP-HPLC and the masses were confirmed by
MALDI- or ESI-MS.
Mass Spectrometry
A protocol to quantify Api88, Api137, and their major
metabolites was established analog to that of oncocin derivatives,
reported recently (Schmidt et al., 2016). Briefly, an Alliance R©
2695 HPLC system was coupled online to an ESI-QqLIT-MS
(4,000 QTRAP R©) equipped with a TurboVTM ion-spray source
and operated in positive ion MRM mode using the Analyst R©
1.6 software. Separation was achieved on a Jupiter C18-column
(internal diameter 1 mm, length 150mm, particle size 5µm, pore
size 300 Å) at 55 ◦C using a linear 5-min gradient from 2.7 to
20.7% aqueous acetonitrile containing ammonium formate (26
mmol/L, pH 3.0). Further details about instrumentation, MRM
optimization, and MS settings are provided as Supplementary
Material (Tables S1–S4, Method M1).
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Metabolites of Api88 and Api137 were identified on a
nanoACQUITY UPLC R© System coupled online to an ESI-LTQ
Orbitrap XLTM-MS (for details see Tables S2, S5). Peptides
enriched by solid phase extraction were separated on a BEH
C18 nanoACQUITY UPLC R© column (100µm internal diameter,
100mm length, 1.7µmparticle size, 13 nm pore size, 30◦C) using
an aqueous acetonitrile gradient from 3 to 30% (within 18 min)
and 30 to 95% acetonitrile (1 min) in the presence of formic
acid (0.1% v/v) at a flow rate of 0.4 µL/min. Differences in the
peptide profiles were identified by comparing the extracted ion
chromatograms (XICs, m/z ± 0.01) of samples obtained from
treated and untreated mice. MassLynxTM software was used to
control the nanoACQUITY UPLC R© and the Orbitrap MS and
XcaliburTM software to process MS data.
Animals and Housing
Female outbred NMRI mice (Janvier Labs, Saint Berthevin
Cedex, France) were housed in an individually ventilated cage
system (Ebeco, Castrop-Rauxel, Germany) under pathogen-
free conditions with water and standard food (R/M-H, ssniff
Spezialdiäten GmbH, Soest, Germany) given ad libitum. After
acclimatization for at least one week, studies were performed
according to the guidelines for the Care and Use of Laboratory
Animals and the study was approved by the Animal Care and
Usage Committee of the state agency Leipzig (Landesdirektion
Leipzig, file numbers 24-9168.11/14/37 and 24-9168.11/17/43).
Female outbred CD-1 mice (Innovo, Gödöllo˝, Hungary) were
acclimatized 1 week after arrival in a sterile plastic type 2 cage
(Innovo Kft., Gödöllo˝) on softwood granules with free access to
water and sterile pelleted rodent food (Szinbád Ltd., Gödöllo˝).
All animals were cared for and experiments were performed in
accordance with the recommendations of the Guidelines for the
Care and Use of Laboratory Animals and the study was approved
by the Animal Care Committees of Semmelweis University
(permission No.: 001/2218-4/2012).
Systemic Septicemia Infection Mouse
Model
The acute toxicity of Api137 was studied by administering doses
of 20, 40, 80, and 120 mg/kg intraperitoneally (i.p.) four times
daily (0, 3, 7, and 24 h) into female NMRI mice (24–32 g, ∼7
weeks old). For in vivo efficacy, female NMRI mice (high dose
experiment: 24–27.1 g, 6 weeks; low dose experiment: 26.8–30.3
g, 7 weeks) were infected intraperitoneal with E. coli ATCC
25922, as described before (Czihal et al., 2012; Knappe et al.,
2012). Briefly, each mouse was infected with 9 × 105 bacteria
in the presence of 2.5% (w/v) mucin (0.3 mL in total). Mucin
restricts acute macrophage activation in the intraperitoneal
space and promotes establishment of a reproducible infection
(Frimodt-Møller et al., 1999). Mice were observed three times
daily for their health status for a total of 5 days post-infection
and weighed 1 day before and 1 and 5 days after infection. In
accordance with the guidelines of the Animal Care and Usage
Committee of the Landesdirektion Leipzig, moribund mice were
euthanized.
Apidaecin Api137 (high dose experiment: 2.5 and 1.25 mg/kg
body weight; low dose experiment: 0.6 and 0.3 mg/kg body
weight) was administered intraperitoneal (0.3 mL) in seven
mice per group three times post-infection (1, 4, and 8 h)
as antibacterial therapy. Each experiment included seven mice
receiving ciprofloxacin (40 mg/kg body weight) and four mice
receiving only the vehicle (5% glucose in water, w/v) as positive
and negative controls, respectively.
Pharmacokinetics
Female NMRI mice (8–9 weeks, 25–35 g) were injected
intraperitoneally (10 mL/kg) with peptides dissolved in sterile
PBS (Gibco R© Life TechnologiesTM, Darmstadt, Germany) at
concentrations of 0.5 or 2 g/L corresponding to doses of 5 or
20 mg/kg body weight, respectively. After 10, 20, 30, 60, or
90 min animals (n = 7) were euthanized by carbon dioxide
inhalation and terminal bleeding via cardiac puncture. Lithium-
heparin plasma (n = 7) was prepared and stored at −80◦C.
Immediately after the final bleed, mice were perfused through
the left ventricle with saline (0.9%, 50 mL, ∼3 min) to remove
blood from all organs controlled by discoloration of the liver.
Organs were removed aseptically and directly frozen in liquid
nitrogen. Spontaneously released urine was collected and frozen
immediately at−80◦C.
Female CD-1 mice (20–23 g weight, 7 weeks) were injected
intravenously (10 mL/kg) in the tail vein with peptides (0.5
g/L) dissolved in sterile saline (0.9%, w/v) corresponding to
doses of 5 mg/kg body weight. Animals (n = 4 per time point
and peptide) were euthanized 5, 10, 20, 40, and 60 min post-
injection by carbon dioxide inhalation and exsanguination. For
further details of sample preparation and recovery experiments
see Supplementary Material (Methods M2, M3).
Peptide Stability in Peritoneal Lavage
Peritoneal lavage (1.5–2 mL) were collected from three
euthanized female CD-1 mice (14 weeks, 32–33 g) after injecting
sterile PBS intraperitoneal (4 mL). Peptides were incubated with
aliquots (95 µL) of fresh lavage (75 µg/mL, 37◦C, 750 rpm).
After 0, 30, and 60 min trichloroacetic acid (25 µL, 15% w/v) was
added to the samples to precipitate proteins, incubated on ice (10
min), and centrifuged (5 min, 12.400 × g). Supernatants were
neutralized with sodium hydroxide (1 mol/L) and analyzed by
RP-HPLC using a Poroshell 120 SB-C18-column (2.1mm internal
diameter, 100 mm length, 2.7 µm particle size, 12 nm pore size,
Agilent Technologies Inc., Santa Clara, CA, USA) at 60◦C and
an aqueous acetonitrile gradient containing trifluoroacetic acid
(0.1%, v/v). Absorbance was recorded at a wavelength of 214 nm.
RESULTS
Intraperitoneal Toxicity and Therapy
When Api137 was administered intraperitoneally four times (0,
3, 7, and 24 h) at doses of 20, 40, and 80 mg/kg per injection,
none of the seven animals per dose group showed any signs of
adverse side effects. Higher doses of 120 mg/kg induced signs of
discomfort in some animals and decreased mobility for up to 20
min after administration, but they recovered completely prior to
the next treatment and all mice survived the observation period
of 5 days.
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As reported previously, Api88 administered intraperitoneally
rescued all NMRI mice in a lethal E. coli ATCC 25922 infection
model at doses of 2.5 and 1.25 mg/kg (Figure 1A; Czihal et al.,
2012). Lower doses of Api88 were not tested, as the scoring
of at least four animals in the low dose group (1.25 mg/kg)
indicated that a further reduction of the dose would have led
to very serious signs of infection and reduced weight (>20%)
demanding euthanasia according to the guidelines of the ethical
committee. Api137 appeared more efficient in this septicemia
model due to the better scores obtained at the same dose and by
rescuing all animals at doses of 0.6 mg/kg and higher and still
four out of seven mice at a dose of 0.3 mg/kg, which represented
approximately the ED50 (Figure 1B). The higher efficacy of
Api137 had no detectable effect on body weights (Figure 1C), as
the body weight losses of the highest dose groups of Api137 and
Api88 (2.5 and 1.25 mg/kg) were comparable. The weight gain
after 5 days post-infection lead to values slightly above the pre-
infection values. Interestingly, animals treated with 2.5 mg/kg
Api88 or Api137 showed similar weight losses as mice treated
with ciprofloxacin at the recommended dose of 40 mg/kg within
the respective experiment. The comparison of both peptides
considering the corresponding ciprofloxacin controls indicates
a slightly better outcome regarding the body weights for Api88,
which may rely on the biological variance.
Pharmacokinetics
A sensitive RP-HPLC-ESI-MS approach for targeted
quantification of Api88, Api137, and their identical metabolites
containing the N-terminal 16 (Api1-16) or 17 residues (Api1-
17) was developed based on a protocol recently reported
for oncocins (Schmidt et al., 2016). The MRM relied on
triply protonated precursor ions and a neutral loss of two
molecules of dimethylamine from the N-terminal N,N,N′,N′-
tetramethylguanidine group, which was highly selective and
sensitive providing limits of quantification (LOQ) from 19 to
59 ng/mL (∼9 to ∼25 nmol/L). Recovery rates were 35 ± 5–56
± 16% after sample preparation with only weak matrix effects
(−4.4 ± 0.2–13 ± 3%). Accuracies were 89 ± 6–116 ± 17%
and intra- and interday precisions were 10% or better for all
peptides and concentrations. Details of the method development
and validation of the optimized method are provided as
Supplementary Material (Tables S4, S6–S9, Figures S1–S3).
Api88 administered intravenously at a dose of 5 mg/kg was
detected at a plasma concentration of 1 µg/mL at the first time
point after 5 min (Figure 2A). Unexpectedly, Api137, which has
a 70 times longer half-life time in mouse serum, injected at
the same dose was detected at a lower concentration of only
0.4 µg/mL in plasma (Figure 2A). The plasma levels of both
peptides further decreased at similar kinetics to concentrations
around the LOQ after 10 min. After 60 min Api137 was still
present at concentrations around the LOQ, while Api88 was not
detected.
Intraperitoneal applications were initially used in the infection
models due to the presumed depot effect providing slower
releases and thus longer circulation times in blood. Indeed,
when Api88 and Api137 were injected intraperitoneal at doses
of 5 mg/kg, slightly lower plasma levels of 0.6 and 0.2 mg/mL,
respectively, were observed after 10 min that decreased even
further during the next 20 min. Api137 was still detected after
1.5 h, whereas Api88 was undetectable (Figures 3A,B, Figures
S4A,B, S5). The calculated initial concentrations (c0) were 0.2 and
1 µg/mL, respectively (Table 1), but the plasma levels decreased
slower than for intravenous applications demonstrating a rather
small depot effect. Again, Api88 was detected at the initial time
points at higher plasma levels than Api137, but the elimination
half-life time of Api137 (t½ = 33.8 min) was almost two-fold
longer than for Api88 (t½ = 17.3 min), which could be explained
by the higher serum stability of Api137.
Four-fold higher doses (20 mg/kg) provided maximal plasma
levels of 4.1 (Api88) and 3.6 µg/mL (Api137) after 10 min,
which was 7- and 17-fold higher than observed for the low
dose (Figures 3A,B). Surprisingly, the c0 values were similar
for both peptides (6.2 and 7.8 µg/mL, respectively), while
the elimination half-life times decreased to 11 and 17 min,
respectively (Table 1). However, the data points indicated an
almost stable plasma level for Api88 over 30 min, whereas
FIGURE 1 | Survival rates (A,B) and relative change of body weights (C) of NMRI mice (n = 7) infected intraperitoneally with E. coli ATCC 25922 (9 × 105 bacteria in
the presence of mucin, 2.5% w/v, 300 µL in total). Api88 (A) and Api137 (B) were administered intraperitoneally (300 µL) at doses of 2.5 and 1.25 mg/kg and 2.5,
1.25, 0.6, and 0.3 mg/kg, respectively, three times post-infection (1, 4, and 8 h). Ciprofloxacin (CIP, 40 mg/kg body weight) and vehicle only (glucose in water, 5% w/v)
were used as positive and negative control, respectively. Mice were controlled three times daily for their health status for 5 days post-infection and weighed 1 day
before and 1 and 5 days after infection. Relative changes of body weights were calculated for Api88, Api137, and ciprofloxacin at 1 and 5 days post-infection (black
and gray bordered bars, respectively). # and ## denote that 6 and 4 survivors were weighed, respectively.
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FIGURE 2 | Pharmacokinetic studies of Api88 and Api137 (A) after intravenous administration at doses of 5 mg/kg BW and the corresponding metabolites
Api1-16 and Api1-17 (B). Peptides were quantified by RPC-ESI-QqLIT-MS for blood samples collected 5, 10, 20, 40, and 60 min after peptide administration (n = 5).
Inserts display the same data points using zoomed concentration ranges.
Api137 was cleared faster resulting in a lower plasma level at
30 min. Although difficult to interpret, a comparison of the
pharmacokinetic parameters clearance and mean residence time
of the high and low dose groups seemed to be similar for Api88
and different for Api137.
Metabolites in Blood
Metabolites Api1-16 and Api1-17, which were identified as
major degradation products of both Api88 and Api137 in serum
stability assays (Berthold et al., 2013), were quantified besides
the full-length peptides by RP-HPLC-ESI-QqLIT-MS using the
optimized MRM method. As expected from serum stability
assays, metabolites Api1-17 and Api1-16 appeared at higher
concentrations (1.2 and 2.9 µg/mL after 10 min, respectively)
for Api88 than for Api137 (<0.1 µg/mL) after intravenous
administration at a dose of 5 mg/kg (Figure 2B). Although,
the low concentrations of both Api137 metabolites are in full
agreement with the higher in vitro stability of Api137, the total
quantities of intact peptide and metabolites was significantly
lower than for Api88.
Intraperitoneal administration yielded Api88, Api1-16, and
Api1-17 at similar plasma levels that remained relatively stable
for the first 30 min (Figure 3C, Figure S4C) indicating again a
depot effect in the peritoneum. In contrast, both metabolites of
Api137 were detected at an equal level that was around six-fold
higher than for the intact peptide after 10 min administered at
a dose of 5 mg/kg (Figure 3D, Figure S4D). For the high dose
group, the ratio was initially around 2. Interestingly, the plasma
levels of the metabolites remained above the levels of Api137
for the first hour and the curves showed a more exponential
shape than for Api137 indicative of a slower clearance rate. The
two administration routes resulted in clearly different metabolite
profiles for both apidaecins. The higher serum stability of
Api137 was not reflected in vivo when it was injected in the
peritoneum. Altogether, the plasma levels of both Api88 and
Api137 were lower than assumed from previous studies on
oncocins, even when considering the major metabolites Api1-
16 and Api1-17. Thus, the plasma samples obtained 10, 30,
and 60 min after intraperitoneal injections were screened for
further degradation products of both peptides using nanoRP-
UPLC-ESI-LTQ-Orbitrap XLTM-MS (Figure S6). For Api88, five
further metabolites with peak areas of 1 to 3% relative to the
full length peptide were identified (Figure S6A), i.e., Api2-
16, Api7-18, Api3-18, Api7-12, and Api1-6 in the order of
decreasing peak areas. Surprisingly, besides Api1-16 and Api1-
17, only three metabolites were detected for Api137 at low
intensities (peak areas <1% relative to Api137), i.e., Api7-12,
Api2-16, and Api2-18 in the order of decreasing peak areas
(Figure S6B). However, numerous metabolites with very low
intensities were observed indicating subsequent degradations,
but their contents did not explain the unexpectedly fast clearance
rates.
Organ Distribution
The low plasma levels and the corresponding high volumes
of distribution (VD) of Api88 and Api137 partially attributed
to C-terminal degradation resulted in recovery rates below 1%
in blood relative to the injected peptide amounts (Tables S10,
S11). The strong accumulation in kidneys and renal excretion
was expected for the short polar peptides, as already noted
for oncocin derivatives (Holfeld et al., 2015; Schmidt et al.,
2016). Therefore, the tissue distribution was further investigated
using homogenates of kidney, liver, and brain besides the
appearance in urine. Api88 and Api137 were detected in kidney
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FIGURE 3 | Pharmacokinetics of Api88 (A) and Api137 (B) and metabolites 1–17 and 1–16 (C,D) after intraperitoneal administration at doses of 5 mg/kg BW and
20 mg/kg BW. Peptides were quantified by RPC-ESI-QqLIT-MS/MS in plasma samples collected at 10, 20, 30, 60, and 90 min post-injection (n = 7).
homogenates of the high dose group with almost stable peptide
concentrations between 0.5 to 0.8µg/g over the first 30 min post-
injection (Figures 4A,B). The peptide concentrations decreased
afterwards, but remained above the LOQ in some animals after
90 min. Four-fold lower doses reduced the kidney levels of
Api137 around four-fold (0.18 to 0.11 µg/g), but only two-
fold for Api88 (0.33 to 0.05 µg/g kidney). In contrast, the
peptide levels in liver homogenates were dose-independent for
both peptides and two-fold higher for Api88 (0.2–0.4 µg/g)
compared to Api137 (0.1–0.2 µg/g) for the first three time
points (Figures 4C,D). Metabolite Api1-16 was detected at
slightly higher concentrations than Api1-17 in kidney and liver
homogenates, but both were present at much lower levels than
Api137 (Figures 4A–D). In contrast, Api88 and its metabolite
Api1-17 were present in both homogenates at similar levels,
while Api1-16 was lower concentrated (Figures 4A,C), which
correlates to their plasma levels. Brain homogenates contained
neither Api88 nor Api137, i.e., less than the LODs of 43 and 18
ng/mL homogenate, respectively, corresponding to∼89 and∼37
µg/g brain nor the two metabolites.
Three to seven mice of the studied groups spontaneously
released urine during euthanasia. Api88 was present in all urine
samples of the high-dose group at similar levels of ∼0.2 µg/mL
(Figure 5A). Urine collected in the low-dose group contained
Api88 at the same level at the first time point, but it decreased
afterwards to concentrations below LOD. The Api137 levels
were similar for both dose groups showing peak concentrations
of ∼0.2 µg/mL in urine at 20 and 30 min, which decreased
afterwards to levels below 0.1 µg/mL (Figure 5B). Metabolite
Api1-17 was detected in the high-dose groups at intensities
between the LOD and the LOQ and undetectable in the low dose
group. The levels of Api1-16 were around the LOQ after 30 and
60 min in the low dose group, but similar to the concentrations
of the full length peptides in the high dose groups.
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TABLE 1 | Mean pharmacokinetic parameters of Api88 and Api137 in mice,
after intraperitoneal administration, determined with PKSolver using the
concentrations for the terminal elimination phase determined by the
software.
Peptide Api88 Api137
Dosage [mg/kg BW] 5 20 5 20
Injected peptide amount [µg] 137 618 145 602
cmax[µg/mL] 0.6 4.1 0.2 3.6
c0[µg/mL] 1.0 6.2 0.22 7.8
t1/2 [min] 17.3 11.1 33.8 16.9
k [min−1] 0.040 0.062 0.020 0.041
Volume of distribution [mL] 137 100 659 77
AUC0→∞ [µg*min*mL
−1] 21.3 114.2 9.6 72.0
AUMC0→∞ [µg*min
2*mL−1] 650 2730 1512 524
Clearance [mL/min] 6.4 5.4 15.1 8.4
Mean residence time [min] 30.5 23.9 54.9 21.0
cmax , c0, t1/2, k, AUC, and AUMC denote maximum concentration, initial concentration
at time point 0 min, elimination half life time, elimination constant, area under the
concentration time curve, and area under the moment curve, respectively.
Peptide Recovery in Blood and Organ
Homogenates
Peptide recoveries were determined by spiking untreated blood
and homogenization buffer with either Api88 or Api137 prior
to heparin plasma preparation or homogenization of organs
obtained from untreated mice. Recovery rates for plasma were 49
± 5 and 78± 5% for Api88 and Api137, respectively (Figure 6A,
Table S12), which was similar to the recovery rates determined for
liver (Api88: 45± 5%, Api137: 49± 4%) and brain homogenates
(Api88: 89 ± 24%, Api137: 42 ± 4%). In contrast, the recovery
rates were much lower in kidney homogenates (17 ± 6 and 3.5
± 0.4%, respectively), which was previously noted for oncocin
peptides as well (Schmidt et al., 2016). Metabolites identified
by nanoRP-UPLC-ESI-Orbitrap-MS in the kidney homogenates
were detected with small signal intensities relative to the full-
length peptides indicating small peptide quantities (Table S13)
that do not explain the low peptide recoveries in the kidneys.
The low recoveries might be related to (i) further degradation
to small peptides missed by the analytics, (ii) different metabolic
pathways (e.g., oxidation), or (iii) strong binding to insoluble cell
compartments that were removed by centrifugation after cell lysis
(analysis of cell debris indicated only small peptide quantities,
data not shown).
The recovery rates obtained from the spiked samples, were
used to calculate the total amounts of intact peptides in
blood, liver, and kidneys after intraperitoneal administration
(Figures 6B–E, Tables S10, S11). The relative recovery in the
studied organs and blood was only around 1.5 ± 0.6–2.1 ± 0.7%
of the injected peptide amounts. Considering the mean weight
of 29 g per mouse in this study and the weights of blood, liver,
two kidneys, and brain with 2.2, 1.5, 0.5, and 0.5 g, respectively
(∼16% of the total weight), around 12% of the injected peptide
quantities were detected in the samples collected at the first
time point considering a homogeneous distribution in the whole
animal. Notably, the recovery rates of Api88 and Api137 were
similarly low and significantly lower than reported for oncocin
analogs Onc72 and Onc112 administered intraperitoneal at a
dose of 5 mg/kg (47 and 32%, respectively) in an equally
performed pharmacokinetic study (Schmidt et al., 2016). In
fact, C-terminal degradation of apidaecins could explain the
difference, as metabolites of oncocins were detected at much
lower amounts (Onc72) or not at all (Onc112). Nevertheless, the
discrepancy between the bioavailability and peptide to metabolite
ratios in vivo (especially for intraperitoneal administration) and
the serum stability assay performed in vitro remained open.
Peptide Stability in Peritoneal Lavage
Peritoneal lavage was not collected during the pharmacokinetic
study, as the main emphasis after euthanasia was the immediate
collection of blood and perfused organs, whereas the discrepancy
between in vitro degradation and in vivo metabolization was
revealed only after completion of the animal studies. Thus, three
untreatedmice were euthanized and the peritoneumwashed with
PBS in order to obtain peritoneal lavage. Peptides Api88, Api137,
Onc72, and Onc112 were incubated in aliquots of the lavage
of each mouse ex vivo and analyzed for the added peptide and
its degradation products after 0, 30, and 60 min. Surprisingly,
Api137 was degraded very fast with a half-life time of ∼20
min yielding Api1-17 as major metabolite (Figure 7A). Api88
was cleaved at the same position, but the amidated C-terminus
reduced the degradation rate with more than 60% of Api88 still
present after 1 h. The total amounts of intact peptide and Api1-
17 reached in both cases almost 100% indicating that no other
metabolites were produced in significant quantities. Onc72 and
Onc112 were evenmore stable withmore than 89% intact peptide
present after 1 h (Figure 7B). Only for Onc72 the metabolite 1–
14 was detected at higher quantities (7% relative to the intact
peptide) after 60 min. It should be noted that the degradation
was studied in lavage diluted with PBS at an unknown ratio and
that the degradation rates in the peritoneum are most likely even
higher. This nicely explains the unexpectedly low concentrations
of Api137 in the pharmacokinetic study compared to Api88
and to oncocin peptides and similarly the surprisingly high
concentrations of metabolites.
DISCUSSION
Apidaecin analogs Api88 and Api137 are similarly active against
Gram-negative bacteria with a tendency of higher activity of
Api88 against K. pneumoniae (Czihal et al., 2012; Berthold
et al., 2013). However, Api88 carries a C-terminal amide
that is responsible for its very fast proteolytic cleavage in
serum, the supernatant obtained after complete coagulation and
centrifugation of blood. The in vitro serum stability assay, which
is an important in vitro criterion to select therapeutic peptides
for systemic applications, yielded very short half-life times of
5 min for Api88, which indicate that the peptide is not well-
suited for in vivo applications, while the 6 h for Api137 are very
favorable (Berthold et al., 2013; Czihal et al., 2012). Taking into
account the comparable minimal inhibitory concentration of∼4
µg/mL against E. coli ATCC 25922, it was predicted that Api137
exhibits a much better in vivo efficacy than Api88 in previous
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FIGURE 4 | Concentration profiles of Api88 (A,C) and Api137 (B,D) and the corresponding metabolites Api1-17 and Api1-16 in kidney (A,B) and liver (C,D)
homogenates. Api88 and Api137 were administered intraperitoneal (5 mg/kg and 20 mg/kg) and quantified in homogenates prepared from organs (n = 5) isolated 10,
20, 30, 60, and 90 min after administration. The hash (#) indicates that the Api1-17 value of one mouse was removed as outlier.
studies, because Api88 would be degraded rapidly after injection.
Surprisingly, the in vivo efficacy of Api137 was only two-fold
better with doses of 0.6mg/kg Api137 rescuing all mice compared
to 1.25 mg/kg Api88. Oncocin analogs Onc72 and Onc112,
which possess MIC values of 16 and 4 µg/mL, respectively,
against E. coli ATCC 25922 (Knappe et al., 2016c), rescued in
the same infection model all animals at doses of 5 and 2.5
mg/kg, respectively (Schmidt et al., 2016). While the MIC values
correlate well to the in vivo efficacies, the pharmacokinetics
differed completely from our expectations considering the serum
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FIGURE 5 | Pharmacokinetics of Api88 (A) and Api137 (B) in urine after intraperitoneal administration at doses of 5 and 20 mg/kg. Both peptides were quantified
in urine (n = 3–7) spontaneously released after anesthetization. Concentrations of metabolites were below LOQ. The hash (#) indicates that one mouse was removed
at this time point from the low dose group as outlier.
stability assays. Maximum plasma levels of Onc72 and Onc112
were up to 10-fold higher than that of Api88 and Api137
after intraperitoneal administration. For the high dose groups,
the concentrations of Api1-16, Api1-17, and the intact peptide
corresponded in total to around 10 and 16µg/mL, whichmatches
well Onc72 (18 µg/mL). The lower dose groups showed total
maximum plasma levels (intact peptides plus metabolites) of 1.7
and 2.8 µg/mL for Api88 and Api137, respectively, which was
around three-fold lower than reported for Onc72 (6 µg/mL)
and Onc112 (8 µg/mL). Metabolites Api1-17 and Api1-16 are
virtually inactive in vitrowith MIC values of 64 µg/mL and>128
µg/mL, respectively. This is most likely related to the reduced
bacterial uptake, as both metabolites bind equally well to the
70S ribosome and DnaK as the intact peptide (Berthold and
Hoffmann, 2014; Krizsan et al., 2014). Although speculative, the
bacterial uptake of the truncated sequences might change in vivo,
as bacteria might activate different transporter systems under
less favorable growing conditions. Additionally, host peptides
increasing the bacterial membrane permeability might assist
shortened peptides to enter bacteria. All other pharmacokinetic
values depicting biodistribution in liver, kidneys, brain, and
urine were lower values for both apidaecin analogs indicating
a reduced overall recovery compared to both oncocin analogs.
Although, the serum half-life times of Onc112 exceeded 8 h
in vitro, Onc72 (3 h) was only half as stable (Knappe et al.,
2011a) as Api137 (6 h), which contradicts the faster in vivo
metabolization of Api137. The apparent discrepancy was solved
by a peritoneal lavage ex vivo stability assay that revealed a
fast degradation of Api137 indicating its fast metabolization
in the peritoneum. Contrastingly, the concentration of Api137
was also slightly lower after intravenous application than for
Api88. As expected from the lower serum stability of Api88,
its metabolites were more abundant in blood, whereas no
metabolites were detected for Api137. As renal excretion of both
peptides appeared to be similar, distribution of Api88 and Api137
might be inconsistent as indicated by their different volumes of
distribution.
Considering the pharmacokinetic data, the high in vivo
efficacies of Api88 and Api137 are surprising. Thus, a drawback
of intraperitoneal sepsis models commonly applied in antibiotic
research has to be discussed, as infection and treatment used
the same route and direct bacterial killing in the peritoneum
starting 1 h post-infection appears very likely. Nevertheless,
the model is accepted for evaluation of antimicrobials and the
bacteria were well-distributed in blood and even organs prior
to treatment (Frimodt-Møller et al., 1999; Knappe et al., 2012).
Additionally, if the in vitro activity would translate to the activity
in the peritoneum and sterilization of the peritoneum would be
the only in vivo effect, Onc112 should show a much higher in
vivo efficacy than Api137 due to its higher peritoneal stability.
However, the plasma concentrations do not substantiate efficient
treatment with either of the four PrAMPs when considering
their in vitro antimicrobial activities determined with standard
MIC-testing methods, which are most likely not the proper
conditions to predict in vivo efficacies of PrAMPs. Synergistic
effects with intrinsic antimicrobial substances produced by
the host, e.g., AMPs like CRAMP, and immunomodulatory
effects could also explain this discrepancy (Ostorhazi et al.,
2013; Otvos and Ostorhazi, 2015; Knappe et al., 2016b). The
latter effect was studied for Onc72, but no immunomodulatory
effects were observed on unstimulated and lipopolysaccharide
(LPS)-stimulated murine dendritic cells or murine macrophages
(Fritsche et al., 2012). Only human macrophages and monocytes
showed a reduction of LPS-induced TNFα release after treatment
with Api88 and Api137 indicating a mild anti-inflammatory
effect (Tavano et al., 2011; Keitel et al., 2013). Unfortunately,
further data on immunomodulatory effects of Api137 on murine
cells are missing.
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FIGURE 6 | Mean recovery rates (n = 3) of Api88 and Api137 spiked to heparin blood or organ homogenates (A) and mean percentage rates recovered in
blood, liver, and kidneys of mice treated intraperitoneal with doses of 20 mg/kg (B) and 5 mg/kg of Api88 (C) or 20 mg/kg (D) and 5 mg/kg of Api137 (E). Peptide
distributions were calculated for plasma (one third of the whole mouse blood volume assumed to be 2.25 mL) and organs assuming that the peptides are present only
in plasma and equally distributed in organ homogenates. Absolute quantities were calculated by assuming a total plasma volume of 25 mL/kg mouse weight and that
organ volume in mL corresponds to the measured organ weight in g.
FIGURE 7 | Peritoneal lavage stability of apidaecins (A) and oncocins (B). Api88 (full diamonds), Api137 (full circles), Onc72 (full squares), and Onc112 (full
asterisks) were incubated in lavage ex vivo and quantified after 30 and 60 min by RP-HPLC. Shown are the quantities of the incubated peptides (full symbols) and their
main metabolites Api1-17 and Onc1-16 (open symbols) normalized to the initial peptide amounts determined at 0 min. The considered monoisotopic masses of the
quadruply protonated metabolites were m/z 545.5 (Api1-17) and m/z 479.5 (Onc1-16) matching very well the signals at m/z 545.6 and 479.5, respectively, recorded
with an Esquire HCT ESI-Iontrap-MS.
Although speculative, the accumulation of the PrAMPs in the
kidneys and possibly spleen (not tested) may lead to high local
concentrations sufficient to kill bacteria in both organs that are
responsible for clearance of bacteria in the blood stream. In this
respect, the lower recovery rates of Api137 spiked to the buffer
before kidney homogenization may indicate a strong binding to
the organ structures, i.e., brush boarder membrane. Therefore,
the recovered peptide amounts in kidneys of Api137 treated
animals (2.4 µg/g) were slightly higher than in Api88 treated
animals (1.8 µg/g). Notably, PrAMPs usually do not penetrate
mammalian cells, but immune cells and HeLa cancer cells can
internalize apidaecins and Bac7(1–35) after long incubation
times (Tavano et al., 2011; Hansen et al., 2012; Pelillo et al.,
2014; Bluhm et al., 2016). However, it is unlikely that PrAMPs
internalized in kidney cells within 10 min (first time point of
the pharmacokinetic study). More likely they bind to membrane
structures or accumulate in the interstitial fluid of the kidney.
Estimating the volume of both kidneys as 0.5 mL, the detected
peptide amount would translate to kidney concentrations of 4.8
µg/mL, which is most likely higher in the interstitial volume and
will easily kill bacteria surrounding kidney cells. In this respect,
it has to be noted that the animals were carefully perfused with
saline after euthanasia in order to remove blood from the organs
and to measure only peptide amounts that are localized in the
organs and not in blood. Considering all data presented above,
it appears reasonable to assume that perfusion did also wash out
peptides bound to the tissue or dissolved in the interstitial fluid.
Therefore, the peptide amounts in the kidney with circulating
blood might have been significantly higher.
Metabolization of therapeutic peptides in the peritoneum
could be suppressed by formulating the peptides with EDTA or
other biocompatible protease inhibitors providing maybe better
in vivo efficacies and better pharmacokinetics. Alternatively,
intramuscular and subcutaneous injections are valid alternative
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routes with depot effects and were already successfully applied
to treat animals (Ostorhazi et al., 2010; Knappe et al.,
2015). Even though, the unexpectedly good pharmacokinetic
profile of Api88 can be only partially explained by its higher
peritoneal stability. Further studies have to explain why Api88
appears much more stable in intravascular blood than in
serum.
Besides the partially unexpected effects, the pharmacokinetic
data may indicate that their therapeutic effects are related to
their maximal blood concentrations and not to the time period
above a certain threshold or the AUC. Our most recent data
indicate an irreversible uptake of Api137 by bacteria into the
cytosol (unpublished data), which may provide an explanation
for their high in vivo efficacy, i.e., the peptide concentration
could fall below the MIC as soon as a certain amount of
PrAMP entered the cells. Earlier studies on fluorophore-labeled
peptides indicated that Api88 enters E. coli cells faster than
Api137 at high quantities, but the data might be influence by
the N-terminally attached dye that reduced also MIC values
(Czihal et al., 2012; Berthold and Hoffmann, 2014). Thus, further
studies using RP-HPLC-ESI-MS techniques to study the cellular
uptake of unmodified Api88, Api137, Onc72, and Onc112 and
to determine the post-antibiotic effect of these peptides are
necessary to quantify their in vitro activities in the context of the
in vivo studies presented here.
CONCLUSION
The data presented here together with literature data allowed
comparing the in vivo efficacy of four PrAMPs, i.e., two apidaecin
analogs Api88 and Api137 and two oncocin analogs Onc72
and Onc112 within and between both peptide families. The
comparison relies on one infection model of peritoneal sepsis
performed in one laboratory by the same persons revealing
that the therapeutic efficacy increased in the following order:
Api137 < Api88 < Onc112 < Onc72. This was not presumable
from the order of stability determined in vitro in mouse serum
(Onc112 > Api137 > Onc72 >> Api88) and the in vitro
antimicrobial activities (Api88 > Api137 = Onc112 > Onc72).
Both parameters are favoring Api137 and Onc112 well above
Api88 and Onc72 with respect to their predicted in vivo efficacy.
The stability in peritoneal lavage as third in vitro parameter
ranked the peptides in a different order (Onc112 > Onc72
> Api88 > Api137) and explains partially the lower than
expected performance of Api137 based on the initial in vitro data.
There are a few possible explanations, e.g., organ accumulation,
immunomodulatory effects, and irreversible bacterial uptake,
to correlate the high in vivo efficacies with the relatively low
plasma concentrations, which is commonly accepted as basis for
antibiotic assessment. However, additional effects besides direct
antimicrobial activity in the bloodstream have to be studied in
more detail and the efficacy in different infectionmodels will help
to justify further clinical development of both apidaecin analogs
and both oncocin analogs.
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